文献速递免疫规划传染病防控与疫情报告

4CMenB疫苗上市后效果真实世界研究合成中的挑战:关于B群脑膜炎球菌疾病的系统综述

Challenges in synthesis of real-world vaccine effects on meningococcal serogroup B disease for 4CMenB vaccine post-licensure effectiveness studies: A systematic review.
PubMed 文献 · Vaccine · 2023-06-14

该系统综述检索2014年1月至2021年7月PubMed、Cochrane及灰色文献中关于4CMenB疫苗对B群脑膜炎球菌疾病真实世界效果的研究,共纳入5项提供疫苗效果(VE)或疫苗影响(VI)估计的研究;因研究人群、接种方案和分析方法差异大,无法进行定量合并,采用描述性方法评估,VE估计范围为59%至94%,VI估计范围为31%至75%,作者指出需要开发适应工具以促进异质性真实世界疫苗研究的合成。

要点

  • 共纳入5项4CMenB疫苗真实世界研究,均报告VE或VI估计值。
  • VE估计范围为59%至94%,VI估计范围为31%至75%,涉及不同年龄组和接种方案。
  • 因研究异质性大,无法应用定量合并方法,采用描述性评估。

核心结论

  • 两种疫苗结局均显示4CMenB疫苗在真实世界中的有效性,尽管研究方法与接种策略存在差异。
  • 基于对研究方法的评估,作者强调需要一种适应工具,以便在无法应用定量合并方法时促进异质性真实世界疫苗研究的合成。

研究设计与样本

  • 系统文献综述,检索PubMed、Cochrane和灰色文献中2013年上市后至2021年7月发表的4CMenB疫苗对B群脑膜炎球菌疾病真实世界效果研究,无人群年龄、接种方案或疫苗效果类型限制。

主要发现

  • 共检索到5项提供4CMenB疫苗效果和影响估计的研究。
  • 这些研究在人群、接种方案和分析方法上差异很大,主要由于研究环境中的疫苗策略和建议不同。
  • VE估计范围为59%至94%,VI估计范围为31%至75%,代表不同年龄组、接种方案和分析方法。

关键数值与推荐

  • VE估计范围为59%至94%。
  • VI估计范围为31%至75%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究在人群、接种方案和分析方法上差异很大,主要由于研究环境中的疫苗策略和建议不同。
  • 由于这种多样性,无法应用定量合并方法合成发现,转而描述性评估研究方法。
  • 作者强调需要一种适应工具,以便在无法应用定量合并方法时促进异质性真实世界疫苗研究的合成。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Real-world studies on vaccine effects are diverse in terms of objectives, study setting and design, data type and scope, and analysis methods. In this review, we describe and discuss four-component meningococcal serogroup B vaccine (4CMenB vaccine, Bexsero) real-world studies with the aim of synthesizing their findings with application of standard methods. METHODS: We performed a systematic literature review of all real-world studies on 4CMenB vaccine effects on meningococcal serogroup B disease, with no restriction for population age, vaccination schedule and/or type of vaccine effect evaluated (vaccine effectiveness [VE] and vaccine impact [VI] outcomes) published since its licensure in 2013 (from January 2014 until July 2021) in PubMed, Cochrane and the grey literature. We then aimed to synthesize the findings of the identified studies through application of standard synthesis methods. RESULTS: According to reported criteria we retrieved five studies presenting estimates on 4CMenB vaccine effectiveness and impact. These studies showed great diversity in population, vaccination schedule and analysis methods mainly due to diversity in vaccine strategies and recommendations in the study settings. Directed by this diversity, no quantitative pooling methods to synthesize findings could be applied; instead we descriptively assessed study methods. We report VE estimates ranging from 59% to 94% and VI estimates ranging from 31% to 75%, representing diverse age groups, vaccination schedules and analysis methods. CONCLUSION: Both vaccine outcomes showed real-life effectiveness of 4CMenB vaccine despite differences in study methodologies and vaccination strategies. Based on appraisal of study methods, we highlighted the need for an adapted tool which facilitates synthesis of heterogenic real-world vaccine studies when quantitative pooling methods are not applicable.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Cinconze E, Rosillon D, Rappuoli R, et al. Challenges in synthesis of real-world vaccine effects on meningococcal serogroup B disease for 4CMenB vaccine post-licensure effectiveness studies: A systematic review. Vaccine. 2023. PMID: 37321895. doi:10.1016/j.vaccine.2023.05.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。